Dr Reddys Lab launches generic version of Aloxi injection

Pharma major Dr Reddy’s Laboratories launched palonosetron hydrochloride injection. The injection is a generic version of ALOXI (palonosetron hydrochloride).

The therapeutic equivalent of Aloxi is approved by the US drug regulatory, USFDA. Aloxi and generic palonosetron hydrochloride injection had US sales of approximately US$446 million in January 2018 (for 12 month period), according to IMS Health data. Dr Reddy’s injection is available in single-dose vial packaged of 0.25 mg/5 mL (free base).

Palonosetron hydrochloride injection is a 5-HT3 receptor antagonists used to prevent nausea and vomiting that sometimes occur post receiving chemotherapy for cancer.

Aloxi is a registered trademark of Helsinn Healthcare, a Swiss-based company. The company settled a patent litigation with Helsinn related to Aloxi generic in 2016.

Meanwhile, the stock of Dr Reddy was trading at Rs. 2,084.65 per share, up by 0.52 per cent on Monday, when the benchmark index BSE Sensex was at 32,914.55, up by 318.01 points or 0.98 per cent.